Search
EHA Lymphoma Group
The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.
Read moreHemaSphere, the Official Journal of the European Hematology Association, Receives Its First Impact Factor
The Hague, June 2022 - HemaSphere, the official peer-reviewed journal of the European Hematology Association (EHA), has received its first Journal Impact Factor™. The preliminary 2021 Journal Impact Factor for HemaSphere is 8.
Read moreEHA and PTHiT Successfully Conclude the Second Joint Virtual Mini Hematology Tutorial
EHA-PTHiT Mini Hematology Tutorial
November 15-16, 2021
Meeting chairs:
Prof G Gaidano (European Hematology Association)
Prof I Hus (Polish Society of Hematology and Transfusion)
Prof T Robak (Polish Society of Hematology and Transfusion)
After a successful mini Tutorial in April 2021, EHA and PTHiT decided to…
Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013
What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.
Read moreCall for interest — EHA Exam Question Writers Group
The call for interest closed on October 7, 2024. EHA would like to appoint four new members of the European Hematology Exam Question Writers Group.
Read moreNobel prize goes to immunotherapy researchers
October 1, Sweden - Cancer kills millions of people every year and is one of humanity’s greatest health challenges.
Read moreNews
New EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect
On May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) came into effect, mandating stricter and more comprehensive certification and testing protocols for in vitro…
Quality of Life and Symptoms
The goals of the SWG are:
To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.